Eurofins CDMO Alphora – Announces Development & Implementation of AI-Powered Salt and Co-Crystal Screening Software

Why It Matters

The technology accelerates solid‑form selection, giving pharmaceutical companies a faster, cheaper path to optimized drug substances and a competitive edge in the market.

Key Takeaways

• AI tool predicts salt/co‑crystal formation accurately
• Cuts screening time and cost dramatically
• Integrated into Eurofins’ full solid‑state workflow
• Supports bioavailability and manufacturing optimization
• Developed with university collaboration, enhancing credibility

Pulse Analysis

Solid‑state forms such as salts and co‑crystals are critical for a drug’s solubility, stability, and manufacturability, yet their discovery traditionally relies on labor‑intensive trial‑and‑error. Recent advances in artificial intelligence have transformed this landscape by enabling predictive modeling that can evaluate thousands of molecular interactions in silico. Machine‑learning algorithms trained on historic crystallization data can now forecast which combinations are most likely to yield viable solid forms, dramatically reducing the experimental burden and shortening the path from candidate to clinical material.

Eurofins CDMO Alphora’s new platform embeds these AI capabilities into a user‑friendly interface that integrates directly with its existing solid‑state R&D workflow. By delivering accurate predictions for both salts and co‑crystals, the software allows clients to prioritize the most promising candidates early, cutting screening cycles by weeks and slashing associated costs. The collaboration with a local university not only validates the scientific rigor of the models but also ensures continuous improvement as new data are incorporated. Coupled with Alphora’s cross‑functional teams—spanning drug substance, drug product, and manufacturing—the tool provides a seamless bridge from computational insight to laboratory execution.

For the pharmaceutical industry, the adoption of AI‑driven screening represents a strategic lever to enhance pipeline efficiency and reduce time‑to‑market. Companies that leverage such technology can improve bioavailability profiles, mitigate manufacturing risks, and respond more swiftly to competitive pressures. Eurofins’ offering positions it as a front‑runner in the CDMO space, where integrated, data‑centric services are increasingly demanded. As regulatory agencies continue to emphasize robust solid‑form justification, tools that deliver transparent, reproducible predictions will become indispensable, likely spurring broader adoption across the sector.